What does PLANET PHARMA do?

PLANET PHARMA is filed with the CBE under the catch-all “Overige zakelijke dienstverlening”, a code that says little about what the company actually does. Private Limited, started on 10 December 1997, 1 establishment.

What is the address of PLANET PHARMA?

The registered office of PLANET PHARMA is located at Rue Calus 41, 1410 Waterloo.

Is PLANET PHARMA still active?

Yes. According to the CBE (31 October 2026) PLANET PHARMA is active, legal situation “Normale toestand”, started on 10 December 1997.

Is PLANET PHARMA registered on Peppol?

Yes, PLANET PHARMA is registered on the Peppol network with ID 0208:0462084937.

What is the enterprise number of PLANET PHARMA?

The enterprise number of PLANET PHARMA is BE0462084937.

When was PLANET PHARMA founded?

PLANET PHARMA was founded on 10 December 1997.

Who are the directors of PLANET PHARMA?

According to the 2025 annual accounts, the directors of PLANET PHARMA are: Gilles Gernaey, Marie Tremouroux.

Is PLANET PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 10 December 1997; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PLANET PHARMA make in 2025?

PLANET PHARMA posted a profit after taxes of € 45,419 in financial year 2025.

What is the revenue of PLANET PHARMA?

As a small company, PLANET PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 65,544.

PLANET PHARMA (Private Limited) - Waterloo - BE0462084937

Dossier PLANET PHARMA, printed on 31 October 2026 from databakkes.be/en/0462084937/planet-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PLANET PHARMA from Waterloo, company number BE0462084937, closed financial year 2025 with a result of € 45,419 after tax. For that financial year PLANET PHARMA recorded a gross margin of € 65,544 and equity of € 165,037. Compared with financial year 2024, the result moved from € 52,533 to € 45,419. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on December 19, 2025.

What it is worth Growing

€ 165,037

▲ 13% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 45,419

▼ 14% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 27,101

▲ 42% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 26,681 paid out

59 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 1,970

▲ 8% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 2,838

▼ 20% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 1,965

▼ 83% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 1,217

▼ 90% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 9,142 Gross margin 2022: € 9,142 First fiscal year in the series	€ 49,264 Gross margin 2023: € 49,264 ▲ € 40,122 vs 2022 (€ 9,142) Favourable step	€ 80,046 Gross margin 2024: € 80,046 ▲ 62% vs 2023 (€ 49,264) Favourable step	€ 65,544 Gross margin 2025: € 65,544 ▼ 18% vs 2024 (€ 80,046) Unfavourable step	▼ 18%
Profit after taxes	€ 199 Profit after taxes 2022: € 199 First fiscal year in the series	€ 72,576 Profit after taxes 2023: € 72,576 ▲ € 72,377 vs 2022 (€ 199) Favourable step	€ 52,533 Profit after taxes 2024: € 52,533 ▼ 28% vs 2023 (€ 72,576) Unfavourable step	€ 45,419 Profit after taxes 2025: € 45,419 ▼ 14% vs 2024 (€ 52,533) Unfavourable step	▼ 14%
Equity	€ 21,191 Equity 2022: € 21,191 First fiscal year in the series	€ 93,766 Equity 2023: € 93,766 ▲ € 72,576 vs 2022 (€ 21,191) Favourable step	€ 146,299 Equity 2024: € 146,299 ▲ 56% vs 2023 (€ 93,766) Favourable step	€ 165,037 Equity 2025: € 165,037 ▲ 13% vs 2024 (€ 146,299) Favourable step	▲ 13%
Total debts	€ 60,519 Total debts 2022: € 60,519 First fiscal year in the series	€ 25,897 Total debts 2023: € 25,897 ▼ 57% vs 2022 (€ 60,519) Favourable step	€ 27,710 Total debts 2024: € 27,710 ▲ 7% vs 2023 (€ 25,897) Unfavourable step	€ 32,902 Total debts 2025: € 32,902 ▲ 19% vs 2024 (€ 27,710) Unfavourable step	▲ 19%
Cash	€ 7,926 Cash 2022: € 7,926 First fiscal year in the series	€ 44,067 Cash 2023: € 44,067 ▲ € 36,140 vs 2022 (€ 7,926) Favourable step	€ 19,098 Cash 2024: € 19,098 ▼ 57% vs 2023 (€ 44,067) Unfavourable step	€ 27,101 Cash 2025: € 27,101 ▲ 42% vs 2024 (€ 19,098) Favourable step	▲ 42%
Retained profit	€ 14,991 Retained profit 2022: € 14,991 First fiscal year in the series	€ 87,566 Retained profit 2023: € 87,566 ▲ € 72,576 vs 2022 (€ 14,991) Favourable step	€ 140,099 Retained profit 2024: € 140,099 ▲ 60% vs 2023 (€ 87,566) Favourable step	€ 158,837 Retained profit 2025: € 158,837 ▲ 13% vs 2024 (€ 140,099) Favourable step	▲ 13%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 26,681 Dividend 2025: € 26,681 Unchanged (€ 0) Unchanged
Bank debt	€ 15,403 Bank debt 2022: € 15,403 First fiscal year in the series	€ 9,089 Bank debt 2023: € 9,089 ▼ 41% vs 2022 (€ 15,403) Favourable step	€ 3,554 Bank debt 2024: € 3,554 ▼ 61% vs 2023 (€ 9,089) Favourable step	€ 2,838 Bank debt 2025: € 2,838 ▼ 20% vs 2024 (€ 3,554) Favourable step	▼ 20%
Balance sheet total	€ 81,710 Balance sheet total 2022: € 81,710 First fiscal year in the series	€ 119,663 Balance sheet total 2023: € 119,663 ▲ 46% vs 2022 (€ 81,710) Unchanged	€ 174,010 Balance sheet total 2024: € 174,010 ▲ 45% vs 2023 (€ 119,663) Unchanged	€ 197,939 Balance sheet total 2025: € 197,939 ▲ 14% vs 2024 (€ 174,010) Unchanged	▲ 14%

Key figures of PLANET PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to PLANET PHARMA?

What happened at PLANET PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Dec 19, 2025 New annual accounts for financial year 2025: profit of € 45,419 (▼ 14% vs 2024). Source: NBB ↗
2022 Marie Tremouroux became a director. NBB
Apr 28, 2000 New establishment in Waterloo. KBO
1997 Gilles Gernaey became a director. NBB
Dec 10, 1997 Start of the company according to the CBE. KBO

In short

From € 199 profit in 2022 to € 45,419 profit in 2025.

Paid € 51,789 in corporate taxes since 2022.

Best year ever: 2023, with € 72,576 profit.

Paid out € 26,681 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Gilles Gernaey

Marie Tremouroux

PLANET PHARMA

SARL Legisana 49%

Behind PLANET PHARMA are Gilles Gernaey and Marie Tremouroux. It owns 49% of SARL Legisana itself.

Directors

According to the 2025 annual accounts

Gilles Gernaey

Director

since 1997

Marie Tremouroux

Director

since 2022

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Calus 41

1410 Waterloo

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0462.084.937
VAT number: BE 0462.084.937
Registered office: Rue Calus 41, 1410 Waterloo
Names & denominations: PLANET PHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 10 December 1997
Peppol: Active · Active since 20 Nov 2020
Activities · NACE: Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗